Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
NVIDIA
NVDA
Vale SA
VALE
KB Home
KBH
US Stock MarketDetailed Quotes
ITOS ITeos Therapeutics
- 7.400
- +0.130+1.79%
Close Feb 14 16:00 ET
- 7.555
- +0.155+2.09%
Post 20:01 ET
270.35MMarket Cap-2.36P/E (TTM)
7.500High7.290Low167.57KVolume7.330Open7.270Pre Close1.24MTurnover0.64%Turnover RatioLossP/E (Static)36.53MShares18.75052wk High0.43P/B195.36MFloat Cap7.06052wk Low--Dividend TTM26.40MShs Float52.430Historical High--Div YieldTTM2.89%Amplitude7.060Historical Low7.409Avg Price1Lot Size
About ITeos Therapeutics Company
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Company Profile
SymbolITOS
Company NameITeos Therapeutics
Listing DateJul 24, 2020
Issue Price19.00
Founded2012
CEODr. Michel Detheux, PhD
MarketNASDAQ
Employees157
Fiscal Year Ends12-31
Address321 Arsenal Street
CityWatertown
ProvinceMassachusetts
CountryUnited States of America
Zip Code02472
Phone1-339-217-0162
Company Executives
- Name
- Position
- Salary
- Dr. Michel Detheux, PhD
- President, Chief Executive Officer and Director
- --
- Matthew Call
- Chief Operating Officer
- --
- Matthew Gall
- Chief Financial Officer and Principal Accounting Officer
- --
- Dr. Yvonne McGrath
- Chief Scientific Officer
- --
- David L. Hallal
- Chairman of the Board
- --
- Dr. Tony Ho, M.D.
- Independent Director
- --
- Ann D. Rhoads
- Independent Director
- --
- David K. Lee
- Independent Director
- --
- Dr. Robert Iannone, M.D.
- Independent Director
- --
- Tim Van Hauwermeiren, M. Sc.
- Independent Director
- --
- Jill DeSimone
- Independent Director
- --
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.